Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jon D Morrow

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
International Urogynecology Journal and Pelvic Floor Dysfunction|January 10, 2009
Continued symptom improvement in sexually active women with overactive bladder and urgency urinary incontinence treated with tolterodine ER for 6 monthsRebecca G Rogers, Tola Omotosho, Gloria Bachmann, et al.
Neurourology and Urodynamics|August 22, 2012
Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trialsCatherine E DuBeau, Jon D Morrow, Stephen R Kraus, et al.
BJU International|September 28, 2010
Early onset of fesoterodine efficacy in subjects with overactive bladderHoward B Goldman, Jon D Morrow, Jason Gong, et al.
The Journal of Urology|March 20, 2012
The effect of elective sham dose escalation on the placebo response during an antimuscarinic trial for overactive bladder symptomsDavid R Staskin, Martin C Michel, Franklin Sun, et al.
Current Medical Research and Opinion|February 4, 2010
Efficacy of fesoterodine over 24 hours in subjects with overactive bladderDavid Staskin, Martin C Michel, Victor Nitti, et al.
International Urogynecology Journal and Pelvic Floor Dysfunction|June 5, 2009
Efficacy and tolerability of fesoterodine in women with overactive bladderPeter K Sand, Jon D Morrow, Tamara Bavendam, et al.
International Urogynecology Journal and Pelvic Floor Dysfunction|August 8, 2008
Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active womenRebecca Rogers, Gloria Bachmann, Zhanna Jumadilova, et al.
BJU International|February 6, 2010
Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trialSender Herschorn, Steven Swift, Zhonghong Guan, et al.
Neurourology and Urodynamics|May 12, 2011
Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladderDavid Staskin, Vik Khullar, Martin C Michel, et al.
Journal of the American Medical Informatics Association : JAMIA|March 26, 2024
Perspectives on the role of industry in informatics research and authorshipHoward R Strasberg, Gretchen Purcell Jackson, Suzanne R Bakken, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
International Urogynecology Journal and Pelvic Floor Dysfunction|January 10, 2009
Continued symptom improvement in sexually active women with overactive bladder and urgency urinary incontinence treated with tolterodine ER for 6 monthsRebecca G Rogers, Tola Omotosho, Gloria Bachmann, et al.
Neurourology and Urodynamics|August 22, 2012
Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trialsCatherine E DuBeau, Jon D Morrow, Stephen R Kraus, et al.
BJU International|September 28, 2010
Early onset of fesoterodine efficacy in subjects with overactive bladderHoward B Goldman, Jon D Morrow, Jason Gong, et al.
The Journal of Urology|March 20, 2012
The effect of elective sham dose escalation on the placebo response during an antimuscarinic trial for overactive bladder symptomsDavid R Staskin, Martin C Michel, Franklin Sun, et al.
Current Medical Research and Opinion|February 4, 2010
Efficacy of fesoterodine over 24 hours in subjects with overactive bladderDavid Staskin, Martin C Michel, Victor Nitti, et al.
International Urogynecology Journal and Pelvic Floor Dysfunction|June 5, 2009
Efficacy and tolerability of fesoterodine in women with overactive bladderPeter K Sand, Jon D Morrow, Tamara Bavendam, et al.
International Urogynecology Journal and Pelvic Floor Dysfunction|August 8, 2008
Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active womenRebecca Rogers, Gloria Bachmann, Zhanna Jumadilova, et al.
BJU International|February 6, 2010
Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trialSender Herschorn, Steven Swift, Zhonghong Guan, et al.
Neurourology and Urodynamics|May 12, 2011
Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladderDavid Staskin, Vik Khullar, Martin C Michel, et al.
Journal of the American Medical Informatics Association : JAMIA|March 26, 2024
Perspectives on the role of industry in informatics research and authorshipHoward R Strasberg, Gretchen Purcell Jackson, Suzanne R Bakken, et al.
Pageof 2